Insights

Innovative Drug Discovery Daiichi Sankyo's recent collaboration with Depixus leveraging MAGNA(TM) technology indicates a strong focus on advancing RNA-targeted therapeutics, presenting opportunities for partnerships or technology licensing to support their R&D efforts.

Growing Market Presence As one of the top 25 global pharmaceutical companies with a substantial workforce and a diverse portfolio of treatments, Daiichi Sankyo provides a substantial market footprint for sales of pharmaceutical products, lab supplies, and healthcare solutions in France.

Digital and Data Optimization With a tech stack that includes advanced security and cloud services like OneTrust and Apple iCloud Mail, there is potential to offer digital transformation solutions, compliance software, or cybersecurity services to support their operational needs.

Focus on Therapeutic Areas Their emphasis on serious health conditions such as cancer, cardiovascular diseases, and inflammatory disorders suggests opportunities to introduce innovative treatment solutions, diagnostics, or medical devices that align with these high-value markets.

Financial Growth Potential With revenue estimates between $10M and $25M and recent strategic collaborations, Daiichi Sankyo France is positioned for growth, making it a promising prospect for expanding pharma supply chains, clinical trial services, or regulatory consulting services.

Similar companies to Daiichi Sankyo France

Daiichi Sankyo France Tech Stack

Daiichi Sankyo France uses 8 technology products and services including TYPO3, OneTrust, Apple iCloud Mail, and more. Explore Daiichi Sankyo France's tech stack below.

TYPO3
Content Management System
OneTrust
Cookie Compliance
Apple iCloud Mail
Email
PHP
Programming Languages
HSTS
Security
X-XSS-Protection
Security
Apache
Web Servers
Apache HTTP Server
Web Servers

Media & News

Depixus partners with Daiichi Sankyo.
PARIS, France - Interactomics pioneer Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA(TM) technology to accelerate the Japanese healthcare leader's RNA-targeted drug discovery program.
Dec 12, 2023 | depixus.com

Daiichi Sankyo France's Email Address Formats

Daiichi Sankyo France uses at least 2 format(s):

Daiichi Sankyo France Email Formats	Example	Percentage
First.Last@daiichi-sankyo.fr	John.Doe@daiichi-sankyo.fr	83%
Last.First@daiichi-sankyo.fr	Doe.John@daiichi-sankyo.fr	17%
FLast@dsi.com	JDoe@dsi.com	91%
LFirst@dsi.com	DJohn@dsi.com	7%
FiLast@dsi.com	JoDoe@dsi.com	1%
First.Last@dsi.com	John.Doe@dsi.com	1%

Frequently Asked Questions

Where is Daiichi Sankyo France's headquarters located?

Daiichi Sankyo France's main headquarters is located at 8-10 Rue Henri Sainte-claire Deville Rueil-malmaison, Île-de-france 92500 France. The company has employees across 4 continents, including EuropeNorth AmericaAsia.

What is Daiichi Sankyo France's official website and social media links?

Daiichi Sankyo France's official website is daiichi-sankyo.fr and has social profiles on LinkedIn.

What is Daiichi Sankyo France's NAICS code?

Daiichi Sankyo France's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Daiichi Sankyo France have currently?

As of April 2026, Daiichi Sankyo France has approximately 182 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Head Of Msl: F. D.Head Of Msls Lung & Gastric Cancers: G. L. G.Head Of Regulatory Affairs & Quality Assurance: A. C.. Explore Daiichi Sankyo France's employee directory with LeadIQ.

What industry does Daiichi Sankyo France belong to?

Daiichi Sankyo France operates in the Pharmaceutical Manufacturing industry.

What technology does Daiichi Sankyo France use?

Daiichi Sankyo France's tech stack includes TYPO3OneTrustApple iCloud MailPHPHSTSX-XSS-ProtectionApacheApache HTTP Server.

What is Daiichi Sankyo France's email format?

Daiichi Sankyo France's email format typically follows the pattern of First.Last@daiichi-sankyo.fr. Find more Daiichi Sankyo France email formats with LeadIQ.

When was Daiichi Sankyo France founded?

Daiichi Sankyo France was founded in 2002.

Daiichi Sankyo France

Q: How many employees does Daiichi Sankyo France have currently?

Daiichi Sankyo France has approximately 182 employees.

Q: What technology does Daiichi Sankyo France use?

Daiichi Sankyo France's tech stack includes Apache, Google Tag Manager, jsDelivr, DocuSign, Google Analytics.

Q: What is Daiichi Sankyo France's NAICS code?

Daiichi Sankyo France's NAICS code is 3254 (Pharmaceutical and Medicine Manufacturing).

Pharmaceutical ManufacturingÎle-de-france, France51-200 Employees

Daiichi Sankyo est un groupe pharmaceutique mondial japonais, basé à Tokyo (Japon) et présent dans plus de cinquante pays.

Né de la fusion en 2005 des laboratoires Daiichi et Sankyo, nous figurons aujourd’hui parmi les 25 laboratoires pharmaceutiques les plus importants au monde et comptons plus de 16 000 salariés dans plus de 20 pays dans le monde. 

Daiichi Sankyo commercialise de nombreux traitements destinés à lutter contre des pathologies importantes : hypertension, dyslipidémie, diabète, syndrome coronaire aigu, maladie thromboembolique veineuse, cancer du sein, mélanome métastasique, maladies inflammatoires, douleur.

Daiichi Sankyo France est une filiale de Daiichi Sankyo Europe GmbH dont le siège est situé à Munich.

Company Overview

Headquarters: 8-10 Rue Henri Sainte-claire Deville Rueil-malmaison, Île-de-france 92500 France
Website: daiichi-sankyo.fr
NAICS Code: 3254 - Pharmaceutical and Medicine Manufacturing
Founded: 2002
Employees: 51-200